Samsung Biologics Revises Roche Contract Size for Contract Manufacturing to Double in One Day

[Asia Economy Reporter Lee Seon-ae] Samsung Biologics' contract manufacturing organization (CMO) scale for biopharmaceuticals ordered from multinational pharmaceutical company Roche nearly doubled in just one day.

On the 28th, Samsung Biologics announced through a revised disclosure that the CMO contract scale with Roche increased from $212.85 million (KRW 234.199 billion) to $403.85 million (KRW 444.356 billion).

This revision was due to an increase in order volume at the customer's request, just one day after the revised disclosure on the 27th.

On the previous day, Samsung Biologics had announced that the CMO contract scale with Roche changed from $35.53 million (KRW 39.094 billion) to $212.85 million (KRW 234.199 billion). Earlier, Samsung Biologics signed a letter of intent for CMO with Roche in June last year and finalized the main contract on January 15 of this year.

The CMO contract scale, which was about KRW 39.1 billion at the time of signing the main contract, surged to KRW 234.2 billion in about eight months, and then to KRW 444.4 billion in just one day. This accounts for 63.34% of last year's total sales.

The contract ends on December 31, 2024.

With this, Samsung Biologics' order amount for this year has exceeded $7 billion. Samsung Biologics' total order amount for the first half of this year is $6.959 billion. The order amount for the first half of this year has already surpassed last year's annual total order amount of $6.1 billion.

This content was produced with the assistance of AI translation services.